A Review on the Pathogenesis, Treatment and Prevention of Peptic Ulcer Disease

Reema Yadav; Jay Kumar; Abhishek Kumar Singh; Anjali Yadav; Prakash Chandra Gupta

Author Guidelines

Submit Manuscript

Editorial Board Member

Membership

Subscription

A Review on the Pathogenesis, Treatment and Prevention of Peptic Ulcer Disease

Reema Yadav

Jay Kumar

Abhishek Kumar Singh

Anjali Yadav

Prakash Chandra Gupta

Asian Journal of Medical Principles and Clinical Practice, Volume 5, Issue 4, Page 183-197

Published: 10 October 2022

Abstract

Peptic ulcer disease, defined as the breakdown of the stomach and/or duodenum's epithelial mucosal barrier, is still a leading source of morbidity and mortality. One of the main etiological factors is H. pylori. using nonsteroidal anti-inflammatory medicines while infected with H.Pylori (NSAIDs). Epigastric Patients frequently experience discomfort, heartburn, reflux symptoms, and nausea. Stomach lining inflammation is a symptom of peptic ulcer disease. The majority of the time, the diagnosis is made after endoscopy of the upper gastrointestinal tract. Ulcer is a prevalent condition that affects people all over the world. Allopathic ulcer treatment has negative health consequences due to unpleasant side effects. Numerous herbal plants and secondary metabolites are now used to treat ulcers.The two most frequent causes of peptic ulcers are infection with Helicobacter pylori or taking non-steroidal anti-inflammatory drugs (NSAIDs), such aspirin. NSAIDs are becoming a more common cause of ulceration, notably ulcers worsened by gastrointestinal (GI) bleeding, as H. pylori infection becomes less common in affluent nations. Only around 15% of people infected with H. pylori develop an ulcer in their lifetime, with the risk being dictated by the virulence of the H. pylori strain, host genetics, and environmental factors (particularly smoking). The inhibition of the gastroprotective cyclooxygenase (COX)-1 enzyme is a major cause of NSAID-induced ulcers.

Keywords:

H. pylori
gastroprotective enzyme
diagnosis
prevention
treatment

How to Cite

Yadav, R., Kumar, J., Singh, A. K., Yadav, A., & Gupta, P. C. (2022). A Review on the Pathogenesis, Treatment and Prevention of Peptic Ulcer Disease. Asian Journal of Medical Principles and Clinical Practice, 5(4), 183–197. Retrieved from https://journalajmpcp.com/index.php/AJMPCP/article/view/140

References

Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo. Med. 2018;115:219–224. [PMC free article] [PubMed] [Google Scholar]

Lanas A., Chan F.K.L. Peptic ulcer disease. Lancet. 2017;390:613–624.

DOI: 10.1016/S0140- 6736(16)32404-7. [PubMed] [CrossRef] [Google Scholar]

Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Quintero E, Perez-Aisa MA, Gisbert JP, Bujanda L, Castro M, Muñoz M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment. Pharmacol. Ther. 2011;33:585–591.

DOI: 10.1111/j.1365-2036.2010.04563.x. [PubMed] [CrossRef] [Google Scholar]

Sonnenberg A. Review article: Historic changes of helicobacter pylori-associated diseases. Aliment. Pharmacol. Ther. 2013;38:329–342.

DOI: 10.1111/apt.12380. [PubMed] [CrossRef] [Google Scholar]

Søreide K., Thorsen K., Harrison E.M., Bingener J., Møller M.H., Ohene-Yeboah M., Søreide J.A. Perforated peptic ulcer. Lancet. 2015;386:1288–1298.

DOI: 10.1016/S0140-6736(15)00276-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Zhang B.B., Li Y., Liu X.Q., Wang P.J., Yang B., Bian D.L. Association between vacA genotypes and the risk of duodenal ulcer: A meta-analysis. Mol. Biol. Rep. 2014;41:7241–7254.

DOI: 10.1007/s11033-014-3610-y. [PubMed] [CrossRef] [Google Scholar]

Datta De D, Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J. Gastroenterol. 2015;21:2883–2895.

DOI: 10.3748/wjg.v21.i10.2883. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Lanas Á, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M, Muñoz M, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin. Gastroenterol. Hepatol. 2015;13:906–912.e2.

DOI: 10.1016/j.cgh.2014.11.007. [PubMed] [CrossRef] [Google Scholar]

Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147:784–792.

DOI: 10.1053/j.gastro.2014.06.007. [PubMed] [CrossRef] [Google Scholar]

Huang JQ, Sridhar S, Hunt RH. Role of helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet. 2002;359:14–22.

DOI: 10.1016/S0140-6736(02)07273-2. [PubMed] [CrossRef] [Google Scholar]

Charpignon C, Lesgourgues B, Pariente A, Nahon S, Pelaquier A, Gatineau-Sailliant G, Roucayrol AM, Courillon-Mallet A. Group de l’Observatoire National des Ulcères de l’AssociationNationale des HépatoGastroentérologues des HôpitauxGénéraux (ANGH) Peptic ulcer disease: One in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment. Pharmacol. Ther. 2013;38:946–954.

DOI: 10.1111/apt.12465. [PubMed] [CrossRef] [Google Scholar]

Levenstein S, Rosenstock S, Jacobsen RK, Jorgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin. Gastroenterol. Hepatol. 2015;13:498–506.e1.

DOI: 10.1016/j.cgh.2014.07.052. [PubMed] [CrossRef] [Google Scholar]

McColl KE. Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol. Clin. N. Am. 2009;38:353–361.

DOI: 10.1016/j.gtc.2009.03.004. [PubMed] [CrossRef] [Google Scholar]

Vinay Kumar, Abbas AK, Nelson Fausto. Robbins and Cotran Pathologic basis of disease. 7th edition. New Delhi. Elsevier India Private Limited; 2006.

Harsh Mohan. Text book of Pathology. 6th edition. New Delhi. Jaypee brother’s medical publisher (P) Ltd; 2013.

Kumar Amandeep, Singh Robin, Sharma Ramica, Kumar Sunil. Peptic ulcer: a review on etiology and pathogenesis. International Research Journal of Pharmacy. 2012;3(6):34-38.

Rakesh Pahwa, Neeta, Vipin Kumar, Kanchan Kohli. Clinical manifestations, causes and management strategies of peptic ulcer disease. International Journal of Pharmaceutical Sciences and Drug Research. 2010;2(2):99-106.

Mohammad A. Al-Mofarreh, Ibrahim A. Al-Mofleh. Esophageal ulceration complicating doxycycline therapy. Word J Gastroenterol. 2003;9:609-611.

Subiksha PS. Various remedies for recurrent Aphthous ulcer: a review. Journal of Pharmaceutical Science and Research. 2014;6(6):251-253.

Crispian Scully, Meir Gorsky, Francina Lozada-Nur. The Diagnosis and management of recurrent Aphthous Stomatitis. The Journal of the American Dental Association. 2003;134(2):200-207.

Brant WE, Helms CA. Fundamentals of diagnostic radiology. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins. 2007;Xix: 1559 .

al-Assi MT, Genta RM, Karttunen TJ, Graham DY. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. Endoscopy. 1996;28(2):229-33.

DOI: 10.1055/s2007-1005433. PubMed PMID: 87

Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 1997;24(1):2- 17. PubMed PMID: 9013343.

Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374 (9699):1449-61.

DOI: 10.1016/S0140-6736(09)60938-7. PubMed PMID: 19683340.

Soreide K, Thorsen K, Harrison EM, Bingener J, Moller MH, Ohene-Yeboah M, Soreide JA. Perforated peptic ulcer. Lancet. 2015;386(10000):1288-98.

DOI: 10.1016/S0140- 6736(15)00276-7. PubMed PMID: 26460663; PMCID: PMC4618390.

Wang SY, Wang HY, Wang TE, Wang HH, Chang WH, Chu CH, Lin SC, Yeh HI, Shih SC. Delayed healing of gastric ulcer is associated with downregulation of connexin 32 in the gastric mucosa, Adv. Dig. Med. 2015;2:67–73.

Available: https://doi.org/10.1016/J.AIDM.2015.01.004.

Li Q, Yang L, Fan L, Liang C, Wang Q, Wen H, Dai J, Li X, Zhang Y. Activity of Bruceajavanica oil emulsion against gastric ulcers in rodents, Asian J. Pharm. Sci. 2018;13:279–288

Available:https://doi.org/10.1016/J.AJPS.2017.12.005.

Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma, Lancet. 1991;338 :1175–1176,

Available: https://doi.org/10.1016/0140-6736(91)92035-Z.

Proctor MJ, Deans C. Complications of peptic ulcers, Surg. 2014;32:599–607.

Available:https://doi.org/10.1016/J.MPSUR.2014.09.005.

Stewart D, Ackroyd R. Peptic ulcers and their complication, Surg. 2011;29:568–569.

Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis, Biomed. J. 2016;39:14–23.

Available: https://doi. org/10.1016/J.BJ.2015.06.002.

Majumdar D, Atherton J. Peptic ulcers and their complications, Surg. 2006;24:110–114.

Available:https://doi.org/10.1383/SURG.2006.24.3.110.

Zhong Q, Shao S, Mu R, Wang H, Huang S, Han J, Huang H, Tian S. Characterization of peptidoglycan hydrolase in Cag pathogenicity island of Helicobacter pylori, Mol. Biol. Rep. 2011;38:503–509.

Available: https://doi.org/10.1007/ s11033-010-0134-y.

Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis, FEBS J. 2011;278:1190–1202.

Available: https://doi.org/10.1111/j.1742-4658.2011.08035.x.

Fagoonee S, Pellicano R. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics, A short review, Infect. Dis. (Auckl). 2019;4235.

Available:https://doi.org/10.1080/23744235.2019.1588472.

Love JW. Peptic ulceration may be a hormonal deficiency disease, Med. Hypotheses. 2008;70:1103–1107.

Available:https://doi.org/10.1016/J.MEHY.2007.12.011.

Lanas A, Chan FKL. Peptic ulcer disease, Lancet. 2017;390:613–624.

Available: https:// doi.org/10.1016/S0140-6736(16)32404-7.

Ilse Truter. Evidence-based pharmacy practice (EBPP): peptic ulcer disease. South African Pharmaceutical Journal 2009;76(1):10-20.

Yuvraj Gulia, Manjusha Choudhary. Peptic ulcer disease: a review. Pharmacologyonline. 2011; 3:48-70.

Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374(9699):1449-61. doi: 10.1016/S0140-6736(09)60938-7. PubMed PMID: 19683340.

al-Assi MT, Genta RM, Karttunen TJ, Graham DY. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. Endoscopy. 1996;28(2):229-33.

DOI: 10.1055/s2007-1005433. PubMed PM

Jayaraman MV, Mayo-Smith WW, Movson JS, Dupuy DE, Wallach MT. CT of the duodenum: an overlooked segment gets its due. Radiographics. 2001;21Spec No:S147-60.

DOI:10.1148/radiographics.21.suppl_1.g01oc01s147. PubMed PMID: 11598254.

Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000;79(6):379-411. PubMed PMID: 11144036.

Carucci LR, Levine MS, Rubesin SE, Laufer I. Upper gastrointestinal tract barium examination of postbulbar duodenal ulcers. AJR Am J Roentgenol. 2004;182(4):927-30.

DOI: 10.2214/ajr.182.4.1820927. PubMed PMID: 15039165.

Garrow D, Delegge MH. Risk factors for gastrointestinal ulcer disease in the US population. Dig Dis Sci. 2010;55(1):66-72.

Lin KJ, Garcia Rodriguez LA, Hernandez-Diaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf. 2011;20(7):718-728.

Kang JY, Tinto A, Higham J, Majeed A. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther. 2002;16(6):1067-1074.

Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29(9): 938-946.

Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107(8):1190-1195; quiz 1196.

Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 1997;24(1):2-17.

Lochhead P, EI-Omar EM. Helicobacterpylori infection and gastric cancer. Best Pract Res Clin Gastroenterol. 2007:21(2):281-297.

Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev.2006;19(3):449-440.

Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004;159(1):23-31.

Tsamakidis K, Panotopoulou E, Dimitroulopoulos D, et al. Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol. 2005;11(42):6644-6649.

Orton DI, Orteu CH, Rustin MH. Cytomegalovirus-associated gastric ulcer in an immunosuppressed patient with pemphigus vulgaris. Clin Exp Dermatol. 2001;26(2):170-172.

Mössner J. The indications, applications, and risks of proton pump inhibitors. Dtsch. Arztebl. Int. 2016;113:477–483.

DOI: 10.3238/arztebl.2016.0477. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Maes M.L., Fixen D.R., Linnebur S.A. Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence. Ther. Adv. Drug Saf. 2017;8:273–297.

DOI: 10.1177/2042098617715381. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Maton PN, Burton ME. Antacids revisited: A review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57:855–870.

DOI: 10.2165/00003495-199957060-00003. [PubMed] [CrossRef] [Google Scholar]

Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: Randomised, lansoprazolecontrolled non-inferiority and single-blind extension study. Gut. 2018;67:1042–1051.

DOI: 10.1136/gutjnl-2017-314010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y, Fujisaki J. Vonoprazan is superior to rabeprazole for healing endoscopic submucosal dissection: Induced ulcers. Digestion. 2018;97:170–176.

DOI: 10.1159/000485028. [PubMed] [CrossRef] [Google Scholar]

Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: Randomised phase 3 study. Gut. 2018;67:1033–1041.

DOI: 10.1136/gutjnl-2017-314852. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Kagawa T, Iwamuro M, Ishikawa S, Ishida M, Kuraoka S, Sasaki K, Sakakihara I, Izumikawa K, Yamamoto K, Takahashi S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment. Pharmacol. Ther. 2016;44:583–591.

DOI: 10.1111/apt.13747. [PubMed] [CrossRef] [Google Scholar]

Tsuchiya I, Kato Y, Tanida E, Masui Y, Kato S, Nakajima A, Izumi M. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. Dig. Endosc. 2017;29:576–583.

DOI: 10.1111/den.12857. [PubMed] [CrossRef] [Google Scholar]

Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al. Management of Helicobacter pylori infection-the maastricht V/Florence consensus report. Gut. 2017;66:6–30.

DOI: 10.1136/gutjnl-2016-312288. [PubMed] [CrossRef] [Google Scholar]

Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM. Taiwan Gastrointestinal Disease and Helicobacter Consortium Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2016;44:427–437.

DOI: 10.1111/apt.13712. [PubMed] [CrossRef] [Google Scholar]

Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clinical Gastroenterology and Hepatology. 2015;13(9):P1616-1624.

Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. 2014;12:177–186.

DOI: 10.1016/j.cgh.2013.05.028. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Lanas A, García‐Rodríguez LA, Polo‐Tomás M, Ponce M, Quintero E, Perez‐Aisa MA, Calvet X. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Alimentary Pharmacology & Therapeutics. 2011;33(5):585-591.

Stanley AJ, Dalton HR, Blatchford O, Ashley D, Mowat C, Cahill A, et al. Multicentre comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage. Aliment PharmacolTher. 2011;34:470–475. [PubMed] [Google Scholar]

Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, Guarner C. Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine. 2013;368(1):11-21.

Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut and Liver. 2017;11(1):27.

Laine L, Jensen DM. Management of patients with ulcer bleeding. Official Journal of the American College of Gastroenterology| ACG. 2012;107(3);345-360.

Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA internal Medicine, 2014;174(11):1755-1762.

Wang CH, Ma MHM, Chou HC, Yen ZS, Yang CW, Fang CC, Chen SC. High-dose vs non–high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2010;170(9), 751-758.

Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opinion on Drug Safety, 2017;16(6):673-685.

Lanas A, Chan FK. Peptic ulcer disease. The Lancet. 2017;390(10094), 613-624.

Behrman SW. Management of complicated peptic ulcer disease. Arch Surg. 2005;140:201–208. [PubMed] [Google Scholar]

Ramakrishnan K, Salinas RC. Peptic ulcer disease. American Family Physician. 2007;76(7):1005-1012.

Laine L, Jensen D M. Management of patients with ulcer bleeding. Official Journal of the American College of Gastroenterology| ACG. 2012;107(3):345-360.

Chan FKL, Wong VWS, Suen BY, Wu JCY, Ching JYL, Hung LCT, Sung JJY. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. The Lancet, 2007; 369(9573):1621-1626.

Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135(1):41-60.

Sostres C, Carrera-Lasfuentes P, Benito R, Roncales P, Arruebo M, Arroyo MT, Lanas A. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Official Journal of the American College of Gastroenterology| ACG. 2015;110(5): 684-689.

García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123(10):1108-1115.

Derogar M, Sandblom G, Lundell L, Orsini N, Bottai M, Lu Y, Sadr–Azodi O. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clinical Gastroenterology and Hepatology, 2013;11(1):38-42.

Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, Hassan C. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47(10):a1-a46..

Laine L. Upper gastrointestinal bleeding due to a peptic ulcer. New England Journal of Medicine. 2016;374(24):2367-2376.

Wong GLH, Au KWL, Lo AOS, Tse YK, Ching JYL, To KF, Chan FKL. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori–negative idiopathic bleeding ulcers. Clinical Gastroenterology and Hepatology. 2012;10(10):1124-1129.

Adinortey MB, Ansah C, Galyuon I, Nyarko A. In vivo models used for evaluation of potential antigastroduodenal ulcer agents. Ulcers; 2013.

Vogel HG. Discovery and evaluation, Pharmacological assays. 2nd Edition. Berlin Springer Publication; 2002.

Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. Journal of Clinical Medicine 2019;8(2):179.

Pension J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med. Toxicol. 1986;1:192–216.

Asian Journal of Medical Principles and Clinical Practice

A Review on the Pathogenesis, Treatment and Prevention of Peptic Ulcer Disease

Abstract

How to Cite

References

Download Statistics

Downloads

Information

Current Issue